1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Cytochrome P450

Cytochrome P450

CYPs

Cytochrome p450 comprises a superfamily of heme-thiolate proteins named for the spectral absorbance peak of their carbon-monoxide-bound species at 450 nm. Having been found in every class of organism, including Archaea, the p450 superfamily is believed to have originated from an ancestral gene that existed over 3 billion years ago. Repeated gene duplications have subsequently given rise to one of the largest of multigene families. These enzymes are notable both for the diversity of reactions that they catalyze and the range of chemically dissimilar substrates upon which they act. Cytochrome p450s support the oxidative, peroxidative and reductive metabolism of such endogenous and xenobiotic substrates as environmental pollutants, agrochemicals, plant allelochemicals, steroids, prostaglandins and fatty acids. In humans, Cytochrome p450s are best known for their central role in phase I drug metabolism where they are of critical importance to two of the most significant problems in clinical pharmacology: drug interactions and interindividual variability in drug metabolism.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-E70480
    Human CYP2A13,Low-Reductase
    Human CYP2A13, Low-Reductase, a recombinant CYP2A13, is a member of the CYP enzyme family and is expressed in human extrahepatic tissues.
    Human CYP2A13,Low-Reductase
  • HY-146688
    SYN20028567
    Inhibitor
    SYN20028567 is an aromatase (CYP19) inhibitor with an IC50 of 9.4 nM. SYN20028567 can be used for breast cancer research.
    SYN20028567
  • HY-E70457
    Human CYP1A2,High-Reductase
    Human CYP1A2, High-Reductase, a recombinant CYP1A2, is one of the most important cytochrome P450 (CYP) enzymes in the liver. CYP1A2 is involved in the metabolism of xenobiotics in the human body.
    Human CYP1A2,High-Reductase
  • HY-158435
    P-gp inhibitor 23
    Inhibitor
    P-gp inhibitor 23 (compound 14F) is a potent inhibitor of P-gp and CYP3A4, with the EC50 and IC50 of 28 nM and 223 nM, respectively.
    P-gp inhibitor 23
  • HY-152159
    CYP4Z1-IN-1
    Inhibitor
    CYP4Z1-IN-1 (compound 7c) is a potent CYP4Z1 inhibitor, with an IC50 of 41.8 nM. CYP4Z1-IN-1 decreases the expression of breast CSCs stemness markers, spheroid formation, and metastatic ability as well as tumor-initiation capability in a concentration-dependent manner in vitro and in vivo.
    CYP4Z1-IN-1
  • HY-17356S1
    Fenofibrate-d4
    Fenofibrate-d4 is the deuterium labeled Fenofibrate[1]. Fenofibrate is a selective PPARα agonist with an EC50 of 30 μM. Fenofibrate also inhibits human cytochrome P450 isoforms, with IC50s of 0.2, 0.7, 9.7, 4.8 and 142.1 μM for CYP2C19, CYP2B6, CYP2C9, CYP2C8, and CYP3A4, respectively[2][3].
    Fenofibrate-d<sub>4</sub>
  • HY-111202R
    Pyributicarb (Standard)
    Activator
    Proguanil (hydrochloride) (Standard) is the analytical standard of Proguanil (hydrochloride). This product is intended for research and analytical applications. Proguanil hydrochloride, an antimalarial proagent, is metabolized to the active metabolite Cycloguanil (HY-12784). Proguanil hydrochloride is a dihydrofolate reductase (DHFR) inhibitor.
    Pyributicarb (Standard)
  • HY-D0145S
    7-Ethoxyresorufin-d5
    Inhibitor
    7-Ethoxyresorufin-d5 is deuterium labeled 7-Ethoxyresorufin. 7-Ethoxyresorufin (Resorufin ethyl ether) is a fluorometric substrate and competitive inhibitor of cytochrome P450, especially CYP1A1. 7-Ethoxyresorufin also inhibits NO synthase[1][2].
    7-Ethoxyresorufin-d<sub>5</sub>
  • HY-146458
    Antibacterial agent 102
    Inhibitor
    Antibacterial agent 102 (compound 32) possesses potent in vitro and in vivo antibacterial activity, with MICs < 0.5 μg/mL in Staphylococcus aureus (S. aureus). Antibacterial agent 102 also moderately inhibits CYP3A4 with an IC50 value of 6.148 μM. Antibacterial agent 102 can reduce Methicillin-resistant Staphylococcus aureus (MRSA) load in thigh infected mice.
    Antibacterial agent 102
  • HY-121789
    Proadifen
    Inhibitor
    Proadifen is a compound that inhibits cytochrome P450 activity, which can change the excitability of catecholamine-secreting neurons in the brain and have different effects on neurons in different brain regions.
    Proadifen
  • HY-116643
    SU 10603
    Inhibitor
    SU 10603 is a specific inhibitor of P45017α (P450c17; CYP17A1).
    SU 10603
  • HY-115754
    S-(N-PhenethylthiocarbaMoyl)-L-cysteine
    Inhibitor
    S-(N-PhenethylthiocarbaMoyl)-L-cysteine (PEITC-Cys), an anticarcinogenic agent, has antileukemic activity. S-(N-PhenethylthiocarbaMoyl)-L-cysteine inhibits DNA synthesis in HL60 cells. S-(N-PhenethylthiocarbaMoyl)-L-cysteine is a P450 inhibitor.
    S-(N-PhenethylthiocarbaMoyl)-L-cysteine
  • HY-E70458
    Human CYP3A4,High-Reductase
    Human CYP3A4, High-Reductase, a recombinant CYP3A4, is a multifunctional enzyme with a wide range of substrates.
    Human CYP3A4,High-Reductase
  • HY-162784
    CYP51-IN-19
    Inhibitor
    CYP51-IN-19 (compound C07) is a potent CYP51 inhibitor. CYP51-IN-19 stimulates reactive oxygen species (ROS) and exhibits potent fungicidal activity.
    CYP51-IN-19
  • HY-13832S3
    cis-Atovaquone-d4
    Inhibitor
    cis-Atovaquone-d4 is deuterium labeled Atovaquone. Atovaquone (Atavaquone) is a potent, selective and orally active inhibitor of the parasite’s mitochondrial cytochrome bc1 complex. Atovaquone is against human and  P. falciparum cytochrome bc1 activity with IC50 values of 460 nM and 2.0 nM, respectively. Atovaquone is an antimalarial agent and has the potential for the investigation of neumocystis pneumonia, toxoplasmosis, malaria, and babesia[1][2].
    cis-Atovaquone-d<sub>4</sub>
  • HY-E70500
    Human CYP4F3,Low-Reductase+b5
    Human CYP4F3, Low-Reductase+b5, a recombinant CYP4F3, is a member of the CYP enzyme family. CYP4F3 is an enzyme mainly expressed in polymorphonuclear leukocytes.
    Human CYP4F3,Low-Reductase+b5
  • HY-106019A
    Liarozole hydrochloride
    Inhibitor
    Liarozole hydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole hydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole hydrochloride shows antitumoral properties.
    Liarozole hydrochloride
  • HY-151253
    CYP2C1/CYP2C19-IN-2
    Inhibitor
    CYP2C1/CYP2C19-IN-2 (compound 21d) is a potent CYP2C9/CYP2C19 inhibitor, possessing no hepatotoxicity and ames toxicity. CYP2C1/CYP2C19-IN-2 can be used in study of anti-ZIKV.
    CYP2C1/CYP2C19-IN-2
  • HY-N3841R
    ε-​Viniferin (Standard)
    Inhibitor
    ε-Viniferin (Standard) is the analytical standard of ε-Viniferin. This product is intended for research and analytical applications. ε-Viniferin (epsilon-Viniferin), the dimer of Resveratrol and can be isolated from Vitis vinifera, displays a potent inhibitory for all the CYP activities, with Ki values from 0.5-20 μM. ε-Viniferin possesses potent antioxidant, anti-inflammatory, anti-diabetic, and anti-neurodegenerative capacity.
    ε-​Viniferin (Standard)
  • HY-N0382S
    Galangin-13C3
    Inhibitor
    Galangin-13C3 is the 13C-labeled Galangin. Galangin (Norizalpinin) is an agonist/antagonist of the arylhydrocarbon receptor. Galangin (Norizalpinin) also shows inhibition of CYP1A1 activity.
    Galangin-<sup>13</sup>C<sub>3</sub>
Cat. No. Product Name / Synonyms Application Reactivity

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.